Stratos Wealth Partners LTD. Sells 2,597 Shares of Danaher Corporation $DHR

Stratos Wealth Partners LTD. decreased its position in Danaher Corporation (NYSE:DHR) by 34.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,944 shares of the conglomerate’s stock after selling 2,597 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Danaher were worth $1,132,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Capital International Investors raised its holdings in Danaher by 1.9% in the third quarter. Capital International Investors now owns 16,758,240 shares of the conglomerate’s stock worth $3,318,926,000 after purchasing an additional 312,951 shares in the last quarter. Generation Investment Management LLP raised its holdings in Danaher by 34.0% in the third quarter. Generation Investment Management LLP now owns 6,654,666 shares of the conglomerate’s stock worth $1,319,354,000 after purchasing an additional 1,689,020 shares in the last quarter. Legal & General Group Plc raised its holdings in Danaher by 5.0% in the third quarter. Legal & General Group Plc now owns 4,452,118 shares of the conglomerate’s stock worth $882,677,000 after purchasing an additional 211,053 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of Danaher by 0.7% in the third quarter. Fisher Asset Management LLC now owns 4,369,219 shares of the conglomerate’s stock worth $866,241,000 after acquiring an additional 28,583 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of Danaher by 23.7% in the third quarter. Invesco Ltd. now owns 3,813,128 shares of the conglomerate’s stock worth $755,991,000 after acquiring an additional 729,597 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 2.8%

NYSE DHR opened at $196.34 on Thursday. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $242.80. The stock has a market cap of $138.95 billion, a P/E ratio of 38.96, a P/E/G ratio of 2.59 and a beta of 0.95. The stock’s fifty day moving average price is $202.14 and its 200-day moving average price is $214.46. The company has a current ratio of 1.87, a quick ratio of 1.51 and a debt-to-equity ratio of 0.35.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, January 27th. The conglomerate reported $2.23 EPS for the quarter, beating the consensus estimate of $2.14 by $0.09. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The company had revenue of $6.84 billion for the quarter, compared to analysts’ expectations of $6.79 billion. During the same period last year, the firm posted $2.14 earnings per share. Danaher’s revenue was up 4.6% compared to the same quarter last year. As a group, equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.8%. This is a boost from Danaher’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Friday, March 27th. Danaher’s payout ratio is 31.75%.

Insider Activity at Danaher

In related news, EVP Gregory M. Milosevich sold 1,320 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total transaction of $274,573.20. Following the sale, the executive vice president directly owned 5,099 shares of the company’s stock, valued at $1,060,642.99. This trade represents a 20.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 11.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. TD Cowen reissued a “buy” rating on shares of Danaher in a research note on Wednesday, January 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Danaher in a research note on Friday, March 27th. Jefferies Financial Group cut their target price on Danaher from $265.00 to $240.00 and set a “buy” rating on the stock in a research note on Wednesday. Leerink Partners increased their target price on Danaher from $260.00 to $270.00 and gave the stock an “outperform” rating in a research note on Friday, January 16th. Finally, Argus set a $265.00 target price on Danaher in a research note on Wednesday, January 14th. Eighteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $251.35.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Evercore ISI kept an Outperform rating on DHR and added the shares to its “Tactical Outperform” list — a vote of confidence from a major research house that can support demand for the stock despite a lower target. Evercore article
• Positive Sentiment: Major analysts (Jefferies, Wolfe) maintained buy/outperform stances on DHR even after adjusting models — indicating continued conviction in Danaher’s long‑term fundamentals and M&A strategy. Jefferies Wolfe
• Neutral Sentiment: Sector context: a recent healthcare roundup notes the industry holding up versus the broader market and highlights companies with solid fundamentals — a neutral tailwind for Danaher given its exposure to diagnostics and life‑science tools. Healthcare sector article
• Negative Sentiment: Multiple firms cut DHR price targets this week (Jefferies: $265 → $240; Wolfe: $260 → $230; Evercore: $254 → $225). Lower targets narrow upside and reflect more conservative near‑term expectations, which can cap gains even with buy/outperform ratings. Jefferies Wolfe Evercore
• Negative Sentiment: An investor‑rights firm is investigating the proposed sale of Masimo to Danaher, probing whether the $180/share offer and the process were adequate — a potential legal/transactional headwind that could delay or complicate the deal and create near‑term uncertainty. Masimo investigation

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.